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ABSTRACT
We present the case of a 61-year-old male who presented with bilateral flank pain and dysuria. 
A biopsy and histopathological analysis of a mass found in the left kidney led to the diagnosis of 
plasmablastic lymphoma (PBL). Initial suspicion of PBL was low, as the kidney is not a typically 
involved organ.1,2 As a part of routine workup, HIV testing was ordered resulting in positive pre-
liminary and confirmatory results. The patient denied awareness of his HIV status. Chemotherapy 
with uricosuric agents and antiretroviral therapy was initiated, but the patient developed tumor 
lysis syndrome with phosphate nephropathy leading to discontinuation of the regimen. Due to 
deterioration in clinical status, the patient chose palliative measures. This case report addresses 
the diagnostic challenges of plasmablastic lymphoma and its rare presentation in an unusual 
location.
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Plasmablastic lymphoma (PBL) is a rare variant of 
non-Hodgkin lymphoma. Characteristic findings are 
a lack of pan B-cell markers, high Ki-67 index, EBV 
positivity, and MYC gene rearrangement.1 Around 
65% of cases of PBL arise in immunocompromised 
individuals.1 Despite its higher prevalence in this 
population, only a small minority of patients present 
with PBL as the initial symptom of immunocompro-
mised status.1,2,3 We present the case of a 61-year-old 
male diagnosed with plasmablastic lymphoma of the 
kidney who later tested HIV-positive. Prior to diagno-
sis, clinical suspicion of PBL was low as the kidney is 
not a commonly reported site of presentation in the 
current literature.1,2
CASE PRESENTATION
Our patient is a 61-year-old male with a past medical 
history of hypertension and blindness who presented 
with bilateral flank pain and dysuria. Initial laboratory 
indices showed acute kidney injury with creatine of 
1.61 and a lactic acid level of 8.82. CT of the abdo-
men showed a large mass in the left kidney extend-
ing along the ureter inferiorly towards the bladder. 
A specimen obtained through CT-guided biopsy 
consisted of diffuse sheets of large plasmablastic 
cells with abundant cytoplasm, vesicular chromatin, 
and prominent centrally located nucleoli (Figures 1A 
and 1B). Frequent mitotic figures, apoptotic bodies, 
and intermixed tingible body macrophages were 
noted. Other pertinent findings included neoplastic 
cells positive for CD45, CD138, CD56, BCL-2, CD10, 
MYC, MUM1, and scattered BCL-6. Immunostains 
for PAX-5, CD79a, and EMA were patchy positive 
with Ki-67 index > 90 with kappa-predominant cells 
present. CD20, CD3, cyclin D1, CD34, CD30, ALK-1, 
CD4, synaptophysin, chromogranin, GATA-3, CK7, and 
CK20 immunostains were negative. Several notable 
findings including lack of pan B-cell markers, EBV 
positive RNA, MYC gene rearrangement, and >90% Ki-
67 immunostains led to the diagnosis of PBL (Figures 
2A, 2B, 2C).
After the diagnosis of PBL, a subsequent PET scan 
visualized the mass in the left kidney with extensive 
lymph node, bone, liver, and muscle metastasis. As 
part of routine workup, HIV testing was ordered. 
Initial and confirmatory HIV tests were positive, 
although the patient denied any awareness of infec-
tion. He denied IV drug use, blood transfusions, or a 
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history of other STDs. 
Upon further testing, 
the patient’s CD4 
count was found to 
be 81, and he was 
given a diagnosis of 
AIDS. The patient was 




ing of tenofovir/emtricitabine and dolutegravir. A 
chemotherapy regimen of Etoposide, Prednisone, 
Vincristine, Cyclophosphamide, and Doxorubicin 
(DA-EPOCH) was initiated with Allopurinol and a dose 
of Rasburicase. During his first cycle of chemothera-
py, the patient developed tumor lysis syndrome with 
phosphate nephropathy. His clinical status deterio-
rated with worsening respiratory status. At this time, 
the patient decided against pursuing aggressive 
treatment measures. His code status was changed to 
comfort measures upon request.
DISCUSSION
Plasmablastic lymphoma commonly occurs in the 
setting of immunodeficiency.4 With regards to HIV in-
fection, the incidence of PBL is approximately 2% of 
all HIV-related lymphomas.5  The differential diagno-
sis in our patient included plasmablastic multiple my-
eloma, Burkitt’s lymphoma, EBV positive diffuse large 
FIGURE 1. (H & E stain): 1A: Low power showing diffuse proliferation of monomorphic 
large cells; 1B: High-power showing large cells with plasmablastic features.
FIGURE 2. (Immunohistochemical stains and EBER): 2A: Positive 
for In Situ Hybridization of EBV-encoded RNA; 2B: high Ki-67 
proliferation index; 2C: Positive staining C-Myc.
™
MARSHALL JOURNAL OF 
MEDICINE
Expanding Knowledge to Improve Rural Health.
mds.marshall.edu/mjm 
© 2021 Marshall Journal of Medicine
Marshall Journal of Medicine 
Volume 7 Issue 3
B-cell lymphoma, and extra cavitary primary effusion 
lymphoma. These pathologies were ruled out due 
to a lack of reconciliation with the histopathological 
features identified in the tumor sample. There are 
characteristics unique to PBL that help distinguish 
it from other etiologies. Biopsied samples lack pan 
B-cell lymphoma markers, and Ki-67 staining index 
is typically high.7 Characteristic immunophenotype 
markers seen in PBL include CD138, CD38, CD79, 
and MUM1.6 Expression of CD4, CD10, and CD56 
have also been reported.6 MYC gene rearrangement 
is found in the majority of PBLs, thus raising suspi-
cion if present.8 In HIV-positive patients, EBV RNA is 
commonly detected.9 Our patient expressed CD138, 
CD56, BCL-2, CD10, MUM1, and scattered BCL-6 pos-
itivity. CD56 and CD10 were positive in the majority 
of cells. Immunostains for PAX-5, CD79a, and EMA 
were also patchy positive. The most noteworthy 
findings our patient had that led to diagnosis were 
EBV positivity, Ki-67 >90%, and MYC gene rearrange-
ment. Although typical immunohistopathological 
findings for PBL were present, there are unique 
features in our patient’s case. The oral cavity, gastro-
intestinal tract, lymph nodes, and skin are the sites 
with the highest incidence of PBL.1,2 The location of 
the tumor within the left kidney found in our patient 
is an atypical presentation. 
Once diagnosed, treatment of PBL comes with 
challenges. Intensive regimens such as etoposide, 
vincristine doxorubicin, cyclophosphamide, and 
prednisone (EPOCH) are preferred over the standard 
regimens of cyclophosphamide, doxorubicin, vincris-
tine, and prednisone (CHOP) used regularly for other 
non-Hodgkin lymphomas.10 Other novel therapies 
such as EBV-targeted cellular immunotherapy, CAR-T 
cell therapy, and MYC targeting agents are currently 
being studied in hopes of a better prognostic out-
come for this highly aggressive tumor.11
CONCLUSION
Our patient’s case suggests that suspicion of PBL 
should be maintained if a tumor specimen has 
immunoblastic or plasmablastic markers even if the 
clinical scenario does not fit the classic presentation. 
Our case may also support testing for etiologies of 
immunocompromised status in patients diagnosed 
with PBL. Though the definitive diagnosis is often-
times challenging, collaboration with a multidis-
ciplinary team consisting of oncology, pathology, 
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